With the original site of the international hotel chain having been established in Singapore almost 140 years ago, the location of the fifth international hotel in Singapore was an appropriate choice for the launch of its fifth international hub in the U.S.: the 5-star Raffles Hotel in Boston.
The officials and business leaders met in a meeting room on the 19th floor on Wednesday evening to mark the opening of Singapore’s newest Overseas Centre, and announced the first agreement made between the Singapore government and a U.S. state to foster mutual economic growth.
Between the lobster, summer rolls, shrimp and curry puffs, guests enjoyed the refreshing Singapore Slings, which were bright pink, gin-based cocktails created at the original Raffles Hotel in 1915.
Expanding the Global Hub Network
Overseas Centres exist in New York, Los Angeles, San Francisco, Austin, and Singapore. The Boston outpost is in Kendall Square, Cambridge, and has been in operation for almost a year, but this week marked the strengthening of economic ties between Boston and the city-state in the Southeast Asia region.
Boston Mayor Michelle Wu attended the event and was bullish on the partnership. The Kendall Square hub “will be their best American office very soon,” Wu said in a speech. Not for nothing were we the city of champions.
As with the other U.S. bases in Singapore, the new site is managed by Enterprise Singapore (EnterpriseSG), which falls under Singapore’s Ministry of Trade and Industry.
Strategic Economic Goals and Key Sectors
EnterpriseSG projects that trade with Massachusetts will more than double from 2021 to 2025, reaching $2.75 billion in 2025. The purpose of the Boston Overseas Centre is to bridge Singapore businesses and the market, providing access to projects, local corporations, and capital networks.
The hub partnership builds on EnterpriseSG’s first partnership in the U.S. with the Massachusetts Office of International Trade and Investment earlier this day, and further strengthens the link between Singapore and Massachusetts businesses in the life sciences, energy, advanced manufacturing, robotics and AI sectors.
The hub will be dominated by some key sectors of interest from Singapore firms, such as life sciences and biotech, Lim added. “Our work in the United States is about building this relationship in the market and forming partnerships with VCs, ecosystem partners, U.S. firms and corporations, so that we open up pathways and doors to Singapore companies and Singapore companies can come here to partner with U.S. firms to develop the solutions and the products.”
Lim said EnterpriseSG will seek to bring Boston VC funders to the attention of businesses in Singapore, building on the knowledge and power of the local biotech industry to help Singapore flourish in the field. She also mentioned the existence of investment firms like Polaris Partners and MPM BioImpact in Singapore already.
VCs from Massachusetts looking to tech scout, do portfolio management, or even look for good deals in Asia might want to do it in Singapore, Lim suggested.
Navigating Singapore’s Biotech Challenges and Successes
The country has been searching for ways to expand its biopharma sector for decades, with biomedical research being the government’s “fourth pillar” of the city-state’s economy in 2000. While Singapore has not yet found its unicorn, the once promising cell therapy biotech Tessa Therapeutics shut its doors in 2023 after some murky trial results, despite raising $200m, a figure that was significantly larger than the funding of other Singapore biotechs at the time.
The news got even more dire in April, when BioNTech announced its intention to close its Singapore facility and move the regional headquarters that it had acquired from Novartis to February 2027.
There have been positive stories, such as drug discovery firm Nanyang Biologics of Singapore, which is a special purpose acquisition company that merged onto the Nasdaq.
Real-World Impact on Startups
The new Singapore-Boston link is already proving to be of benefit to others. Singapore and Boston are home to a biotech startup firm called preclinical therapeutics company Cirrus Therapeutics, working on gene therapies for AMD and other chronic blinding diseases.
“There’s a great synergy between these two sites,” Cirrus CEO Ying Kai Chan said in an interview. The concentration of scientific talent, clinical talent, and drug development talent is half and half between the 2 sites; we’ve worked synergistically to take these therapies to patients, particularly.
Prior to this official opening, Cirrus was working with the hub and engaging with organisations in Singapore to help them manage clinical trials, including, for example, getting in touch with the best hospitals and potential investigators.
Mutual Investments and Regional Leadership
At the event, EnterpriseSG’s Managing Director Cindy Khoo noted that Singapore-based VC firm Vertex Holdings—no connection to the biopharma with the same name—has already invested $100 million in nine Massachusetts startups, including Waltham-based CDMO ElevateBio.
As the first trade office to open in Massachusetts in Southeast Asia, we are dedicated to developing connections between Massachusetts and Singapore and also to the role of connecting Massachusetts to the opportunities, growth and talent of Southeast Asia as a whole,” Khoo said.
Massachusetts Secretary of the Executive Office of Economic Development Eric Paley, who was also present, announced that the state could take cues from how Singapore pursues economic growth internationally.
A Financial Times/Nikkei ranking has made Boston the leading U.S. city for foreign multinationals.
Mayor Wu explained how the daughter of the revolutionary Paul Revere lived in Singapore during the event because her husband was the first U.S. consul to the region. Maria’s family had a foundry in Boston, and they manufactured bells that are now antiques. She commissioned a bell to be made by them for a church in Singapore.
Singapore has established a biotech-focused hub in Boston, building on the long-standing relationship between the two regions and strengthening collaboration in life sciences and biotechnology. The new Boston presence is expected to create opportunities for companies, researchers, investors, and innovators to connect across two important global biotechnology ecosystems.
Boston is widely recognized as a major center for biotechnology, pharmaceutical research, academic science, and healthcare innovation. By expanding its presence in the city, Singapore aims to strengthen access to scientific expertise, investment networks, and emerging technologies.
The Future of Boston Biotech Partnerships
The new initiative highlights the growing value of global partnerships in life sciences. Boston continues to attract international organizations seeking access to scientific expertise, investment networks, and innovative biotechnology companies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
